LDS/Medical Tests/CBFB-MYH11 inv(16) Gene Fusion, Quantitative

CBFB-MYH11 inv(16) Gene Fusion, Quantitative

The CBFB-MYH11 inversion [inv(16)(p13q22)] is a recurrent chromosomal abnormality observed in a subset of patients with acute myeloid leukemia (AML), especially the M4Eo subtype, which is characterized by myelomonocytic blasts and abnormal eosinophils in the bone marrow and peripheral blood. The abnormality results from the inversion of chromosome 16, leading to fusion between the CBFB (core-binding factor beta) gene at 16q22 and the MYH11 (myosin heavy chain 11) gene at 16p13. This fusion disrupts the normal function of core-binding factor (CBF), a transcriptional regulator critical for hematopoietic differentiation, resulting in arrested maturation and uncontrolled proliferation of immature myeloid cells.

Detection of the CBFB-MYH11 fusion transcript serves as both a diagnostic and prognostic marker in AML. Patients harboring this rearrangement generally have a favorable prognosis and respond well to chemotherapy compared to other AML subtypes. Quantitative testing allows for minimal residual disease (MRD) monitoring and early detection of relapse following treatment.

  • Confirms diagnosis of AML M4Eo (acute myelomonocytic leukemia with eosinophilia).
  • Serves as a prognostic marker for favorable outcome in AML.
  • Enables quantitative monitoring of minimal residual disease (MRD) during and after therapy.
  • Assists in assessing risk of relapse and response to treatment.

Positive: Detection of CBFB-MYH11 fusion transcript is consistent with AML M4Eo or related subtypes and supports diagnosis and/or monitoring of disease status.

Negative: Absence of the CBFB-MYH11 fusion transcript suggests the patient is unlikely to have AML M4Eo, though other AML subtypes or molecular abnormalities may be present.

Negative

Quantitative Real-Time Reverse Transcription PCR (qRT-PCR) for fusion transcript detection and quantification, Fluorescence In Situ Hybridization (FISH) for cytogenetic confirmation of inv(16).

Blood, Bone marrow (Lavender, EDTA).

Stability

  • Ambient: 2-3 days
  • Refrigerated: 3-5 days
CBC, PBS, CEBPA gene mutation analysis, PML-RARA translocation, NPM1 gene mutation analysis, BCR-ABL translocation.
3-7 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login